e-Therapeutics plc (e-Therapeutics) is a drug discovery and development company. The Company�s product pipeline includes ETS2101, ETX1153c, ETX1153a and ETS6103. In March 2012, the Company announced that regulators in the United States and the United Kingdom had approved plans for phase I testing of our cancer drug candidate ETS2101. ETX1153c is a product, which combines two active ingredients to produce a potent effect against the bacterium C. difficile, a cause of serious bowel infections. ETX1153a is a topical anti-infective for resistant hospital-based infections. ETS6103 is being developed for depressive disorder.